One patient with quiescent lupus completed hypofractionated breast RT with grade 1 dermatitis
A 31-year-old patient with quiescent lupus and DCIS completed hypofractionated whole-breast RT plus boost with only grade 1 acute dermatitis.
A 31-year-old patient with quiescent lupus and DCIS completed hypofractionated whole-breast RT plus boost with only grade 1 acute dermatitis.
In 801 node-positive breast cancer patients, three-week comprehensive regional nodal IMRT showed similar overall acute toxicity and less grade ≥2 dermatitis.
Among 85 radiation oncologists, nearly half reported age-based chemotherapy omission, while only 25% routinely used geriatric screening.
Updated ASTRO guidance favors moderate hypofractionation for all risk groups, supports five-fraction SBRT in selected patients, and restricts ultrahypofractionated pelvic nodal RT to trials.
In high-risk breast cancer, 16-fraction postmastectomy RT achieved noninferior five-year locoregional control and reduced severe acute skin toxicity versus 25 fractions.
New ARS consensus supports 60 Gy in 15 fractions for selected peripheral tumors but recommends more conservative schedules near critical structures.
Hypofractionated postmastectomy RT met noninferiority criteria for reconstruction complications, with 24-month rates of 12.3% versus 10.2% after conventional RT.
In 68 cervical cancer patients, pelvic marrow dose correlated with hematologic toxicity, supporting stricter exploratory constraints for 44 Gy in 20 fractions.
In 2,057 women, hypofractionated breast RT showed less acute pain and skin toxicity, while severe late effects remained uncommon.
44 Gy in 20 fractions shortened cervical cancer treatment by seven days but showed numerically more severe late GI toxicity.
Each one-point increase in baseline IPSS independently increased the odds of late grade ≥2 GU toxicity by 11%.
Across 26 studies, fatal toxicity clustered when BED10 >100 Gy was delivered to the whole tumor with concurrent platinum chemotherapy.
PACTUS 40 Gy/10 produced 30-month median survival in 28 selected frail patients, but incomplete response and toxicity data limit efficacy conclusions.
A systematic review argues that α/β is disease- and context-specific rather than a fixed biological constant across radiotherapy settings.
Sequential 55 Gy in 20 fractions achieved 62% three-year locoregional control, outperforming conventionally fractionated sequential chemoradiotherapy without greater toxicity.